LABT: LABT: Nu-3 gel patents granted in Australia & New Zealand; global IP now ~71 granted/28 pending

AI Summary

Lakewood-Amedex (LABT) announced two new patents granted in Australia and New Zealand covering the gel formulation of its lead antimicrobial Nu-3, expanding protection for the topical product. The company says its global Bisphosphocin patent estate now totals about 71 granted and 28 pending applications (~99 total) covering composition, formulation and use; the Nu-3 gel is being advanced into Phase 2 for mildly infected diabetic foot ulcers. Lakewood-Amedex plans an initial Phase 2a safety/dose-response study followed by a placebo-controlled Phase 2b to determine dosing and regimen.

Positives

Two patents granted in Australia and New Zealand specifically covering the Nu-3 gel formulation
Global portfolio reported at ~71 granted patents and 28 pending applications protecting composition, formulation and uses
Nu-3 gel is being advanced into Phase 2 clinical studies for mildly infected diabetic foot ulcers

Negatives

No new clinical efficacy or safety data were included in this announcement
Latest patents are jurisdiction-specific additions (Australia and New Zealand) and do not by themselves secure global exclusivity
Patents do not guarantee regulatory approval or commercial success for Nu-3